Outcome | Studies (n) | FE: effect size [95% CI] | RE: effect size [95% CI] |
---|---|---|---|
Macular edema | 2 studies (n = 657)* | RR = 0.22 [0.03–1.67] | RR = 0.22 [0.03–1.64] |
OR = 0.21 [0.03–1.69] | OR = 0.21 [0.03–1.70] | ||
Reduced visual acuity | 3 studies (n = 1123)** | RR = 0.64 [0.24–1.67] | RR = 0.64 [0.17–2.40] |
OR = 0.61 [0.21–1.77] | OR = 0.61 [0.21–1.77] | ||
Vitreous hemorrhage | 3 studies (n = 1123)** | RR = 0.30 [0.07–1.39] | RR = 0.18 [0.02–1.65] |
OR = 0.28 [0.06–1.38] | OR =0.16 [0.02–1.54] | ||
Eye pain | 3 studies (n = 1123)** | RR = 0.80 [0.29–2.21] | RR = 0.78 [0.27–2.21] |
OR = 0.79 [0.26–2.38] | OR = 0.76 [0.24–2.38] | ||
Increased intraocular pressure | 3 studies (n = 1123)** | RR = 0.08 [0.02–0.42] | RR = 0.13 [0.01–1.79] |
OR = 0.07 [0.01–0.37] | OR = 0.11 [0.01–1.54] | ||
Cataract | 3 studies (n = 1123)** | RR = 0.42 [0.13–1.39] | RR = 0.43 [0.12–1.63] |
OR = 0.40 [0.11–1.40] | OR = 0.41 [0.10–1.64] |